- Trial phase
- Phase 1 (IND cleared, trial not yet initiated)
- Time to market
- Unknown, Phase 1 trial has not started; typical development timeline for a rare pediatric cancer drug from Phase 1 to approval is 5-10+ years, if successful.
- Why 3/10
- STAR-001 has no scheduled binary catalyst in the next ~12 months. The IND was cleared in March 2026, but Phase 1 trial initiation and initial data are likely well over a year away. The drug is one of several pipeline assets at a company with a ~$34M market cap, and more advanced programs (LP-300, LP-184) are the primary value drivers. Per the rubric, an early-stage drug with no near-term dated catalyst scores 3.
STAR-001 has no scheduled near-term binary catalyst, the IND was cleared in March 2026 but Phase 1 trial enrollment and initial data are likely 12+ months away. The stock is more driven by LP-300 HARMONIC trial data, LP-184 regulatory progress, and the company's cash runway (only through mid-Q1 2027). Monitor for Phase 1 trial initiation announcements and any partnership/licensing deals that could fund development.
Price Chart
Executive Summary
STAR-001 is an early-stage investigational drug from Lantern Pharma Inc. (Nasdaq: LTRN) being developed for pediatric central nervous system (CNS) cancers, specifically Atypical Teratoid Rhabdoid Tumor (ATRT) and other rare pediatric cancers. On March 30, 2026, the FDA cleared Lantern Pharma's Investigational New Drug (IND) application, allowing the company to proceed with a planned Phase 1 clinical trial. The IND clearance was a positive catalyst, driving the stock up ~22% in one day and ~45% in five days. However, STAR-001 remains in the earliest clinical stage with no disclosed trial start date or data readout timeline. Lantern Pharma has a market cap of roughly $34M, cash runway only through mid-Q1 2027, and multiple other pipeline assets (LP-300, LP-184, LP-284) that are more advanced. STAR-001 is a small part of a broader pipeline with no near-term binary catalyst, making it a low-impact program for investors at this stage.
How It Works
STAR-001 is an investigational drug being developed for rare pediatric brain cancers. Its precise mechanism of action is not publicly detailed, but it is being developed under Lantern Pharma's Starlight pediatric oncology program, which leverages the company's RADR AI platform to identify drug candidates for genomically defined cancers. The drug targets Atypical Teratoid Rhabdoid Tumor (ATRT), a rare and aggressive pediatric CNS tumor driven by SMARCB1 gene mutations.
Trial Status
FDA cleared the IND on March 30, 2026, for a planned Phase 1 pediatric CNS cancer trial in ATRT and other rare pediatric cancers. The trial has not yet been initiated or posted on ClinicalTrials.gov as of available data.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 trial initiation announcement (no date disclosed)
- Initial safety/tolerability data from Phase 1 (likely 12+ months away)
- Potential partnership or licensing deal for STAR-001 or Starlight program
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Lantern Pharma Inc. 8-K LTRN ·Originating report